Research progress of rivaroxaban drug metabolism and gene polymorphism / 中华全科医师杂志
Chinese Journal of General Practitioners
;
(6): 705-709, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-885378
ABSTRACT
Rivaroxaban is one of the new oral anticoagulants (NOAC) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation. It has clear pharmacokinetic parameters, stable plasma concentration, less drug-drug interaction and higher compliance of patients. However, the discrepancy of pharmacokinetics between individuals and drug-induced hemorrhage events frequently occur clinically, therefore the association of gene polymorphism with drug metabolism has become a research hotspot. This article reviews the research progress on pharmacokinetic characteristics of rivaroxaban and its relationship with gene polymorphism, to provide a reference for the individualized rational use of rivaroxaban.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
Chinese Journal of General Practitioners
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS